Hypertension
Details of the Concept
Hypertension is the most prevalent and modifiable cardiovascular risk factor, affecting 46.7% of US adults (2017–2020 NHANES). It is classified into four BP tiers: Normal (<120/80 mmHg), Elevated (120–129/<80 mmHg), Stage 1 (130–139/80–89 mmHg), and Stage 2 (≥140/90 mmHg). The 2025 AHA/ACC guideline adopts PREVENT™ as the CVD risk tool (replacing PCEs) and establishes a universal BP goal of <130/80 mmHg. Hypertension is a leading cause of stroke, heart failure, atrial fibrillation, CKD, dementia, and all-cause mortality.
Key Facts
Classification
- BP Categories (2025 AHA):
Category SBP DBP Normal <120 mmHg and <80 mmHg Elevated 120–129 mmHg and <80 mmHg Stage 1 HT 130–139 mmHg or 80–89 mmHg Stage 2 HT ≥140 mmHg or ≥90 mmHg - Diagnosis requires average of ≥2 readings on ≥2 separate occasions (sources/HT-AHA-2025, rating: very high)
- Prevalence: overall 46.7%; highest in Black adults (56–57%), age 75–80 (83–85%), men (49.5%) (sources/HT-AHA-2025, rating: very high)
PREVENT™ Score (Replacing PCEs)
- PREVENT™ (Predicting Risk of CVD EVENTs) derived from 3.2 million individuals (1992–2022); contemporary, diverse, race-free model (sources/HT-AHA-2025, rating: very high)
- Estimates total CVD (MI + stroke + HF), not just ASCVD; applicable ages 30–79; includes eGFR, statin use, social deprivation index (SDI)
- PCEs overpredicted risk 2-fold; PREVENT has excellent calibration across race/ethnic groups
- Treatment threshold lowered from PCE ≥10% to PREVENT ≥7.5% for initiating medication at SBP ≥130 mmHg
Treatment Thresholds
- All adults with SBP ≥140 or DBP ≥90: initiate antihypertensives (COR 1, LOE A) (sources/HT-AHA-2025, rating: very high)
- CVD, diabetes, CKD, or PREVENT ≥7.5%: initiate if SBP ≥130 or DBP ≥80 (COR 1, LOE A)
- PREVENT <7.5%: initiate if SBP ≥130/DBP ≥80 remains after 3–6 month lifestyle trial (COR 1)
- Goal for all: SBP <130 mmHg; encourage <120 mmHg if tolerated (COR 1 for high-risk; COR 2b for lower-risk)
Lifestyle Management
- DASH eating plan: most effective single lifestyle intervention; −5 to −8 mmHg SBP (sources/HT-AHA-2025, rating: very high)
- Sodium: <2300 mg/d recommended; ideal <1500 mg/d; ~1 mmHg SBP per 1 mmol reduction
- Potassium-based salt substitutes: COR 2a — useful for home food preparers; caution in CKD and with RAASi/K-sparing diuretics
- Aerobic + resistance + isometric exercise all lower BP; isometric exercise: −5 to −10 mmHg SBP
- Alcohol: optimal goal abstinence; SBP rises with any level of intake
- Weight loss: ~1/1 mmHg SBP/DBP per kg lost; ≥5% body weight reduction for meaningful effect
Medical Management
- First-line agents: Thiazide-type diuretics, long-acting dihydropyridine CCB, ACEi, ARB
- Stage 2 HT or high CVD risk: Start 2 agents as single-pill combination (SPC) preferred over separate pills (COR 1, LOE A); improves adherence and reduces time to control (sources/HT-AHA-2025, rating: very high)
- Avoid: ACEi + ARB combination (hyperkalemia, AKI); non-DHP CCB + BB (bradycardia)
- Beta-blockers: Not first-line for uncomplicated HT; preferred if CCD, HFrEF, or arrhythmia
- Up to 50% of patients non-adherent at 1 year; once-daily SPC dosing improves adherence
BP Monitoring
- HBPM + cointerventions (telehealth, medication titration) recommended for monitoring treatment (COR 1, LOE A)
- Cuffless devices and smartwatches: NOT recommended — insufficient validation (COR 3: No Benefit) (sources/HT-AHA-2025, rating: very high)
- ABPM: confirms white-coat and masked hypertension; nighttime BP provides additional CVD risk information
Cuffless BP Devices — Detailed Position (2026 AHA Scientific Statement)
- The 2026 AHA Scientific Statement (sources/cuffless-bp-aha-2026, rating: high) provides a comprehensive overview of cuffless technology mechanisms (PPG, tonometry, PAT, PTT) — see concepts/Cuffless-BP-Monitoring
- Key conclusion: current cuffless devices are "currently may be inappropriate for clinical use" — no device has demonstrated adequate validation, calibration stability, or outcomes correlation
- Specific performance failures: poor tracking of exercise-induced, nocturnal, antihypertensive treatment-induced, and ambulatory BP changes — often no better than baseline cuff calibration-only model
- FDA 510(k) clearance ≠ measurement accuracy; ~80% of cuff-based devices globally lack published validation data; cuffless percentage even higher
- International validation protocol for intermittent cuffless devices (ISO 81060-7) is still in development (as of 2026)
- PPG-based devices show skin tone bias (melanin absorption); most cleared devices not validated across diverse skin tones
- Many patients are already using cuffless devices for BP self-monitoring without disclosing to clinicians — creating a clinical communication gap
Secondary Hypertension
- Present in 5–25% of cases; more common with resistant HT, Stage 2 HT, early onset (<30 y)
- Most common causes: OSA (25–50%), CKD (14%), Primary aldosteronism (5–25%), Drug-induced (2–20%)
- All resistant hypertension: Screen for primary aldosteronism regardless of hypokalemia (COR 1, LOE B-NR) — hypokalemia absent in 50–80% of primary aldosteronism cases (sources/HT-AHA-2025, rating: very high)
- Continue most antihypertensives (except MRA) during initial aldosterone/renin screening
Resistant Hypertension
- Definition: Above goal on ≥3 drugs (complementary mechanisms, including diuretic at max tolerated dose) OR at goal on ≥4 drugs
- Prevalence: 8.5–20% of hypertensive US adults; 50% higher risk of MI/stroke/ESKD vs non-resistant HT; only 23% of all US adults with hypertension achieve BP control (<130/80 mmHg) (sources/rnd-aha-2024, rating: high)
- Evaluate for: white-coat effect, non-adherence, interfering medications, secondary HT
- 4th agent (COR 1): Spironolactone 25–50 mg/d (if eGFR ≥45 mL/min); superior to alpha-blocker or bisoprolol; reduces SBP by 6.6–8.7 mmHg
- Alternatives if MRA not tolerated: amiloride, beta-blockers, alpha-blockers, clonidine, aprocitentan (dual ERA)
Renal Denervation (RDN)
- See concepts/Renal-Denervation for full procedure details, device types, trial data, and patient selection framework
- Guideline class: COR 2b (2025 AHA) — adjunctive treatment for carefully selected patients after lifestyle + medication optimisation (sources/HT-AHA-2025, rating: very high)
- FDA approval (Nov 2023): Medtronic Symplicity Spyral (radiofrequency) and Recor Medical Paradise (intravascular ultrasound) (sources/rnd-aha-2024, rating: high)
- Mechanism: Catheter-based ablation of renal sympathetic nerves → reduced renin release, sodium reabsorption, and renal vascular resistance
- Efficacy across spectrum:
- Drug-naive patients: 4.7–8.5 mmHg daytime SBP reduction vs sham (majority of trials positive)
- On 1–5 medications: more variable; 3.2–7.4 mmHg in positive trials
- Resistant hypertension with standardised background therapy: 4.5–5.9 mmHg reduction (DENERHTN, RADIANCE-HTN TRIO)
- Ultrasound-based RDN outperforms radiofrequency in head-to-head comparison (RADIOSOUND-HTN)
- Response rate: 60–70% achieve ≥5 mmHg reduction; 24% reach target BP <135/85 mmHg vs 12% sham
- vs Spironolactone: Two trials (DENERVHTA, Prague-15) show unipolar RF RDN is inferior or equivalent to spironolactone as 4th agent; combination of MRA + RDN not yet studied
- Safety: No kidney function impairment; serious adverse events <1%; renal artery stenosis 0.2%/year (similar to natural rate); no late safety signals at 3 years (sources/rnd-aha-2024, rating: high)
- Selection: Confirm with 24h ABPM; exclude secondary HT (primary aldosteronism screening mandatory); exclude contraindications (pregnancy, FMD, stented/stenosed/aneurysmal renal artery, renal/adrenal tumours); multidisciplinary team required (COR 1)
- Limitations: No CVD outcomes trial data; no validated biomarker to predict responders; cost vs generic medications unknown; all RCT endpoints are BP-based only
Comorbidities
- Diabetes: ACEi/ARB recommended if eGFR <60 or albuminuria ≥30 mg/g (COR 1, upgraded from COR 2b); SBP goal <130 mmHg (encourage <120 mmHg)
- CKD: SBP goal <130 mmHg; RAASi (ACEi or ARB, not both) if albuminuria ≥30 mg/g; eGFR dip ≤30% acceptable
- Atrial Fibrillation: HT has highest attributable risk for AF; BP goal <130/80 mmHg reduces AF incidence and MACE
- Heart Failure Prevention: HT antecedent in 71% of HF; SBP <130 mmHg reduces HF incidence
- HFrEF: GDMT uptitration; avoid non-DHP CCB; dihydropyridine CCB acceptable if BP remains elevated
- HFpEF: RAASi (ARNi/MRA/ARB); SGLT2i; diuretics; BB NOT recommended for BP control (negative chronotropy)
- Dementia prevention: SBP goal <130 mmHg — COR 1 (upgraded from COR 2a); SPRINT-MIND legacy data show 7-year benefit (sources/HT-AHA-2025, rating: very high)
- Aortic disease: BP <130/80 mmHg; BB preferred; abdominal aortic aneurysm rupture risk +30% per 10 mmHg
- PAD: SBP <130/80 mmHg; ACEi/ARB first-line; no evidence antihypertensives worsen claudication
Stroke
- Acute ICH (SBP 150–220): Lower to 130–<140 mmHg for ≥7 days; avoid SBP <130 mmHg (COR 2a) (sources/HT-AHA-2025, rating: very high)
- Post-EVT reperfusion (large vessel occlusion) — SBP <140 mmHg within 72h — COR 3: HARM: ENCHANTED2/MT trial — intensive lowering to <140 mmHg after successful EVT (mTICI 2b/2c/3) increased death and disability; optimal post-EVT target is 140–180 mmHg for ≥72h (sources/ais-aha-2026, rating: very high)
- Post-IVT (no EVT): Maintain <180/105 mmHg; SBP <140 mmHg target post-IVT — COR 3: No Benefit (sources/ais-aha-2026, rating: very high)
- Secondary stroke prevention: SBP/DBP goal <130/80 mmHg (COR 1); thiazide/ACEi/ARB preferred (sources/HT-AHA-2025, rating: very high)
- See entities/Ischemic-Stroke for full AIS management including EVT selection, thrombolysis, and acute BP targets
Pregnancy
- Treat severe acute HT (≥160/110 mmHg confirmed within 15 min) to <160/110 mmHg within 30–60 min (COR 1)
- Chronic HT: treat to BP <140/90 mmHg (COR 1) — CHAP trial confirmed that treating mild chronic HT reduces APOs without increasing SGA
- Low-dose aspirin 81–150 mg/day from 12–16 weeks for preeclampsia prevention in high-risk women (≥1 high or ≥2 moderate risk factors): reduces preeclampsia by 10–20% sources/ht-pregnancy-aha-2022 (rating: high)
- Contraindicated: Atenolol (fetal growth restriction), ACEi, ARB, direct renin inhibitors (fetal renal development), nitroprusside, MRA/spironolactone (antiandrogenic) (COR 3:Harm)
- Safe first-line agents: labetalol, long-acting nifedipine, methyldopa — equivalent per Cochrane review
- Severe acute HT: parenteral labetalol, parenteral hydralazine, or oral nifedipine — comparable
- Controversy: US ACOG threshold ≥160/110 mmHg vs international consensus ≥140/90 mmHg; CHIPS trial supports tighter control (achieved 133/85 mmHg) without adverse fetal outcomes sources/ht-pregnancy-aha-2022 (rating: high)
- Postpartum: ~60% of maternal deaths occur in first year postpartum; furosemide RCT showed 60% reduction in persistent postpartum HT at day 7; NSAIDs — conflicting evidence on postpartum BP elevation
- History of HDP: sex-specific CVD risk enhancer (HF HR 2.7, stroke HR 1.9, ESKD RR 6.6 after preeclampsia); annual BP/CVD risk assessment; aspirin in future pregnancies; early CVD risk factor control
- See concepts/Hypertensive-Disorders-of-Pregnancy and concepts/Preeclampsia for full HDP detail
Contradictions / Open Questions
- PREVENT vs ASCVD-only tools: PREVENT estimates total CVD (adds HF) whereas ASCVD-focused guidelines (cholesterol) still use ASCVD-only outputs — creates potential risk category mismatches for the same patient
- Optimal BP target in HFpEF: No RCT data directly establishing BP target; extrapolated from general hypertension trials
- DBP J-curve: Post-hoc SPRINT data suggest J-curve for DBP and coronary events; no fixed lower limit established in RCTs; clinical monitoring recommended
- RDN efficacy: Inconsistent across trials; early negative trials (SYMPLICITY HTN-3, REDUCE HTN:REINFORCE) vs positive newer trials with better technique and drug surveillance; no CVD outcome data; head-to-head vs spironolactone shows inferiority or equivalence (DENERVHTA, Prague-15); optimal patient selection criteria still undefined (sources/rnd-aha-2024, rating: high)
- RDN vs spironolactone sequencing: Should spironolactone always be tried before RDN in resistant hypertension? Combination of MRA + RDN not yet studied
- RDN reinnervation in humans: Animal models show partial/full reinnervation with persistent BP reduction; human durability data from registries only (no sham control)
- Post-kidney transplant BP: No robust RCT evidence for specific targets or drug class
- Asleep BP: It remains unclear whether isolated nocturnal hypertension (high asleep, normal awake BP) warrants treatment; no high-quality RCT evidence
Connections
- Related to concepts/ASCVD-Risk-Assessment (PREVENT™ replaces PCEs)
- Related to entities/Atrial-Fibrillation (highest attributable risk)
- Related to entities/Heart-Failure (antecedent in 71% HF)
- Related to concepts/HFpEF (HT as major HFpEF driver)
- Related to entities/Obstructive-Sleep-Apnea (secondary HT, 25–50% prevalence)
- Related to concepts/LV-Diastolic-Function (hypertension → LVH → diastolic dysfunction)
- Related to concepts/Drug-Induced-Arrhythmia (drug-induced secondary hypertension)
- Related to concepts/Cuffless-BP-Monitoring (2025/2026 AHA position: not recommended for clinical use)
- Related to entities/Ischemic-Stroke (post-EVT BP harm; secondary stroke prevention targets)
- Related to concepts/Renal-Denervation (catheter-based adjunctive treatment for resistant/uncontrolled HT)
- Related to concepts/Hypertensive-Disorders-of-Pregnancy (BP thresholds and targets in pregnancy)
- Related to concepts/Preeclampsia (preeclampsia as strongest independent predictor of future hypertension, OR 11.6)